Histone Deacetylase Inhibitors as Cancer Therapeutics

Histone Deacetylase Inhibitors as Cancer Therapeutics

1st Edition - November 1, 2012

Write a review

  • Editor: Steven Grant
  • eBook ISBN: 9780123946089
  • Hardcover ISBN: 9780123943873

Purchase options

Purchase options
DRM-free (EPub, PDF, Mobi)
Available
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. This thematic volume looks at "Histone Deacetylase Inhibitors as Cancer Therapeutics."

Key Features

  • Provides invaluable information on the exciting and fast-moving field of cancer research
  • This thematic volume looks at "Histone Deacetylase Inhibitors as Cancer Therapeutics"
  • Outstanding and original reviews

Readership

Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.

Table of Contents

  • Contributors

    Preface

    Chapter One. Histone Deacetylase Inhibitors Disrupt the Mitotic Spindle Assembly Checkpoint By Targeting Histone and Nonhistone Proteins

    Abbreviations

    1. Introduction

    2. HDACi Dysregulate Cell Cycle Progression

    3. HDACi Disrupt Normal Mitosis

    4. Mechanism of HDACi-Induced Aberrant Mitosis

    5. Conclusions

    References

    Chapter Two. Mechanisms of Resistance to Histone Deacetylase Inhibitors

    1. Introduction

    2. Mechanisms of Resistance to HDAC Inhibitors

    3. Clinical Trials of HDAC Inhibitors

    4. Conclusion

    References

    Chapter Three. HDAC Inhibitors: Roles of DNA Damage and Repair

    1. Introduction

    2. HDACis and DNA Damage

    3. HDACis and Oxidative Stress

    4. SIRTs: DNA Damage and Oxidative Stress Responses

    5. Concluding Remarks and Future Directions

    References

    Chapter Four. HDAC Inhibitor Modulation of Proteotoxicity as a Therapeutic Approach in Cancer

    1. Background: The Cellular Response to Proteotoxicity

    2. Proteotoxicity as a Therapeutic Target in Cancer

    3. Summary and Future Directions

    References

    Chapter Five. Intrinsic and Extrinsic Apoptotic Pathway Signaling as Determinants of Histone Deacetylase Inhibitor Antitumor Activity

    1. Introduction

    2. The Intrinsic Apoptosis Pathway

    3. HDACi Induce Apoptosis Via the Intrinsic Apoptosis Pathway

    4. The Effects of HDACi on Antiapoptotic Bcl-2 Family Genes

    5. Effects of HDACi on Proapoptotic BCL-2 Family Members

    6. Effects of HDACi on Bid

    7. Effects of HDACi on Bim

    8. Effects of HDACi on Bmf

    9. Effects of HDACi on Bad

    10. Effects of HDACi on Noxa/Puma

    11. Effects of HDACi on Bax and/or Bak

    12. The Extrinsic Apoptosis Pathway

    13. Effects of HDACi on the Extrinsic Apoptosis Pathway

    14. Effects of HDACi on DR and Their Ligands

    15. Concluding Remarks

    References

    Chapter Six. Histone Deacetylase Inhibitors and Rational Combination Therapies

    Abbreviations

    1. Introduction

    2. Histone Deacetylases

    3. Histone Deacetylase Inhibitors

    4. Determinants of HDAC Inhibitor Lethality

    5. HDACI Strategies in Cancer Therapy

    6. Summary and Future Directions

    References

    Chapter Seven. HDAC Inhibitors and Chaperone Function

    1. Introduction

    2. HDAC Inhibitors

    3. Chaperones and Protein Homeostasis

    4. Regulation of Hsp90 Chaperone Function by Reversible Acetylation

    5. HDAC3 is the Nuclear Hsp90 Deacetylase

    6. HDAC Inhibitor-Mediated Regulation of Hsp70

    7. HDAC Regulation of Hsp40

    8. Regulation of GRP78 Function by HDAC6

    9. Concluding Remarks

    References

    Index

Product details

  • No. of pages: 288
  • Language: English
  • Copyright: © Academic Press 2012
  • Published: November 1, 2012
  • Imprint: Academic Press
  • eBook ISBN: 9780123946089
  • Hardcover ISBN: 9780123943873

About the Serial Volume Editor

Steven Grant

Ratings and Reviews

Write a review

There are currently no reviews for "Histone Deacetylase Inhibitors as Cancer Therapeutics"